StatLab Activates New U.S. Manufacturing Capabilities to Secure Supply for Domestic Pathology Labs
MCKINNEY, Texas, May 01, 2025--(BUSINESS WIRE)--StatLab Medical Products ("StatLab"), a leading global innovator of pathology supplies, today announced the launch of new U.S.-based manufacturing capabilities, advancing its multi-year "in-region, for-region" strategy to ensure reliable, scalable production of critical reagents for pathology labs nationwide. The latest milestone—insourcing injection-molded prefill containers—further strengthens StatLab's position as one of the top U.S. manufacturers of formalin prefills, producing nearly 100 million units annually, while increasing supply chain reliability for labs amid ongoing global uncertainty.
StatLab has a long history of manufacturing StatClick™ formalin prefills, but by becoming the first in its industry to vertically integrate container and lid production in-house, it is increasing control and reducing supply chain risk for this essential product used in operating rooms and labs every day across the U.S. In addition to bringing injection molding for prefill containers in-house, StatLab will also begin blow molding gallon bottles in Q2. Production capacity for cassettes continues to grow as well, with new injection molding cells added at the Arlington facility to meet strong U.S. demand.
"At StatLab, it is in our DNA to invest ahead of the need," said Sung-Dae Hong, CEO of StatLab. "As one of the market leaders for essential pathology consumables, insourcing key containers for the products we make, including gallon bottles and prefills, empowers us to control quality and protect our customers against external market forces."
In another proactive move to support customers through challenging market conditions, StatLab has announced it will currently absorb any tariff-related fees associated with products manufactured in its European facilities when selling directly to U.S. laboratories. These products include PiSmart cassette and slide printers, KT microscope slides, and KT coverglass. By leveraging its U.S. and European manufacturing capabilities, StatLab is able to offer consumables for the full pathology workflow protected from tariff impact, empowering domestic customers to focus more on patient care.
"Delivering stability for our customers, especially in times of volatility, is part of the trust we build every day," continued Hong. "We recognize the importance of predictable pricing and reliable access to the essential supplies labs need for accurate diagnoses."
About StatLab Medical Products
StatLab Medical Products has been dedicated to helping anatomic pathology laboratories provide the best possible patient care since 1976. Today, with the strength of our united brands and locations around the globe, we're innovating pathology essentials, together. We offer an extensive portfolio of self-manufactured consumables and pathology equipment, developed and produced across nine manufacturing sites in the United States, United Kingdom, and Europe. Our global operational footprint — powered by over 750 mission-driven colleagues — enables an "in-region, for-region" manufacturing strategy, delivering a resilient, dependable supply chain and high-quality solutions. With a customer-centric approach at our core, we bring reliability, innovation, and quality to every interaction. Learn more at StatLab.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250501519536/en/
Contacts
Jessica Baerjbaer@statlab.com 630-346-1659

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


USA Today
29 minutes ago
- USA Today
New NFL crocs look cozy but have have 1 major flaw
The NFL has announced a multiyear licensing deal with the footwear company Crocs, which should allow for some comfortable Sunday viewing sessions. Many sports fans and players, including Dallas Wings rookie Paige Bueckers, enjoy wearing Crocs. Earlier this year, Las Vegas Raiders rookie Ashton Jeanty showed up to the 2025 NFL Draft wearing the crystal-covered clogs. 'The Crocs brand has made a significant impact on footwear culture with their shoes becoming synonymous with ease and comfort,' said Ryan Samuelson, vice president of consumer products at the NFL. 'Collaborating with Crocs allows us to give fans expanded gameday options that will keep them stylishly comfortable for gameday and every day.' The original release, which will drop on September 18 for $84.99, will feature 14 NFL teams. The initial line includes the Kansas City Chiefs, Philadelphia Eagles, Detroit Lions, San Francisco 49ers, Pittsburgh Steelers, Chicago Bears, Buffalo Bills, Las Vegas Raiders, Dallas Cowboys, Miami Dolphins, Minnesota Vikings, Cincinnati Bengals, Houston Texans, and Denver Broncos. Many of them look normal and inoffensive and seem perfectly suited for a casual hang: Some of them, like the pair for the Cowboys, look fairly normal. But the attached Jibbitz™ charms for the Bears, Bills, and Vikings are a bit more odd. These shoes should not have horns! Aside from aesthetic issues, that would make it quite difficult to walk. Similarly, the shoes for the Bears should not have claws. That was a bold decision that isn't working. If these are detachable, there's less of an issue. But if this is a permanent part of the shoe, it's a glaring problem for anyone who hopes to take themselves seriously.


Business Insider
37 minutes ago
- Business Insider
Morning Movers: Dayforce surges after potential Thoma Bravo acquisition reports
Stock futures are drifting lower this morning as investors lean into a busy week headlined by Jackson Hole central bank speeches and earnings from major retailers. Small caps are showing outperformance, suggesting rotation after recent megacap strength, particularly in tech. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Geopolitical developments are adding weight as markets are monitoring the potential implications of President Trump's meeting with Ukrainian President Zelensky and European leaders as Washington seeks support for a Ukraine–Russia peace initiative. In pre-market trading, S&P 500 futures fell 0.09%, Nasdaq futures fell 0.14% and Dow futures are flat. Check out this morning's top movers from around Wall Street, compiled by The Fly, and subscribe to the Fly By if you want to know how the markets will open, which stocks will be moving and why. HIGHER – Dayforce (DAY) up 25% after Bloomberg reported Thoma Bravo is in talks to acquire the company Soho House (SHCO) up 16% after entering into definitive agreements pursuant to which an investor group led by MCR and its chairman and CEO Tyler Morse will acquire the outstanding shares not held by certain significant shareholders TeraWulf (WULF) up 11% after reporting Google (GOOGL) will provide an incremental backstop of $1.4B in support of project-related debt financing and will receive warrants to acquire shares of TeraWulf common stock Tonix Pharmaceuticals (TNXP) up 4% after announcing that the FDA approved Tonmya for the treatment of fibromyalgia in adults Novo Nordisk (NVO) up 4% after announcing that the FDA has approved an additional indication for Wegovy based on a supplemental New Drug Application for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis in adults with moderate to advanced liver fibrosis DOWN AFTER EARNINGS – Riskified (RSKD) down 13% LOWER – Strategy (MSTR) and Coinbase (COIN) both down 1% after bitcoin dipped as heightened macro concerns triggered more than $500M in forced selling of long positions. Tesla (TSLA) down 1% after The Times reported British motorists can lease a Tesla EV for about half the cost it was a year ago as the company attempts to boost its faltering sales in the UK


CNBC
2 hours ago
- CNBC
The 'Halftime' Investment Committee debates the critical week ahead for stocks
The Investment Committee debate this critical week for stocks as central bankers gather in Jackson Hole for their annual get-together. Plus a historic meeting at the White House today as European leaders and President Zelensky meet President Trump to discuss the Russia-Ukraine War.